

10081009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1613sxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPlus records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded

NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:17:36 ON 02 DEC 2003

=> g

G IS NOT A RECOGNIZED COMMAND

=> fil req

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 1 DEC 2003 HIGHEST RN 622782-89-2

DICTIONARY FILE UPDATES: 1 DEC 2003 HIGHEST RN 622782-89-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

 $\Rightarrow \vee$


Uploading 10081009b.str

L1 STRUCTURE UPLOADED

$$\Rightarrow d$$

L1 HAS NO ANSWERS

L1 STR



10081009

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:18:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3005 TO ITERATE

33.3% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 56813 TO 63387
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:18:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 59384 TO ITERATE

100.0% PROCESSED 59384 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.09

L3 17 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 13:18:20 ON 02 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Dec 2003 VOL 139 ISS 23
FILE LAST UPDATED: 1 Dec 2003 (20031201/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3 full

L4 2 L3

=> d l4 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:152636 CAPLUS

DOCUMENT NUMBER: 134:208135

TITLE: Preparation of peptidomimetics as inhibitors of
tryptase activityINVENTOR(S): Weber, Lutz; Fuchs, Thilo; Illgen, Katrin; Doemling,
Alexander; Cappi, Michael; Nerdinger, Sven

PATENT ASSIGNEE(S): Morphochem A.-G., Germany

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014320	A1	20010301	WO 2000-EP8238	20000823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19939910	A1	20010301	DE 1999-19939910	19990823
EP 1206444	A1	20020522	EP 2000-953198	20000823
EP 1206444	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003507450	T2	20030225	JP 2001-518410	20000823
US 2002137687	A1	20020926	US 2002-81009	20020220
PRIORITY APPLN. INFO.: DE 1999-19939910 A 19990823				
WO 2000-EP8238 W 20000823				
OTHER SOURCE(S): MARPAT 134:208135				
AB Compds. X-Ar-NR3CHR4CONR8CHR5CONR6R7 [X is H2NC(:NH) or R1N:C(NH2), where R1 is OH, CO2R2, alkyl, aralkyl, aralkyloxy, or heteroalkyl and R2 is alkyl, heteroalkyl, carbocyclyl, heterocycloalkyl, aryl, heteroaryl, or aralkyl; Ar is arylene, heteroarylene, or aralkylene where X is directly attached to the arom. ring system; R3 is H, alkyl, heteroalkyl, or aralkyl; R4 is H, (un)substituted alkyl, heteroalkyl, carbocyclyl, heterocycloalkyl, aryl, heteroaryl, or aralkyl; R5 is H, alkyl, heteroalkyl, carbocyclyl, heterocycloalkyl, aryl, heteroaryl, or aralkyl; R6 and R7 are H, (un)substituted alkyl, heteroalkyl, carbocyclyl, or heterocycloalkyl; R8 is H, alkyl, heteroalkyl, carbocyclyl, heterocycloalkyl, aryl, heteroaryl or aralkyl] or a pharmaceutically acceptable salt, solvate, hydrate or formulation were prepd. as tryptase inhibitors. Thus, a soln. of glycolaldehyde, 3-aminobenzamidine dihydrochloride, and N-[2-(1H-indol-3-yl)ethyl]-3-methylbutanamide-2-isonitrile in methanol, allowed to react for 24 h at room temp. in a sealed vessel, afforded 2-{[2-({3-[amino(imino)methyl]phenyl}amino)-3-hydroxypropanoyl]amino}-N-[2-(1H-indol-3-yl)ethyl]-3-methylbutanamide hydrochloride, which showed IC50 = < 0.09 and 5 .mu.M for inhibition of tryptase and factor Xa, resp.				
IT 328550-69-2P 328550-70-5P 328550-71-6P				
328550-72-7P 328550-73-8P 328550-76-1P				

10081009

328550-78-3P 328550-80-7P 328550-99-8P


328551-18-4P 328551-47-9P 328551-87-7P

328551-91-3P 328552-38-1P 328552-49-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptidomimetics as inhibitors of tryptase activity)

RN 328550-69-2 CAPLUS


CN Valinamide, N-[3-(aminoiminomethyl)phenyl]seryl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 328550-70-5 CAPLUS


CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]glycyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 328550-71-6 CAPLUS

CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]alanyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


10081009



●x HCl

RN 328550-72-7 CAPLUS


CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]-2-(1H-pyrazol-3-yl)glycyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 328550-73-8 CAPLUS

CN Valinamide, N-[3-(aminoiminomethyl)phenyl]-O-ethyl-3-oxoseryl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 328550-76-1 CAPLUS

CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]seryl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)


10081009



●x HCl

RN 328550-78-3 CAPLUS


CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]valyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 328550-80-7 CAPLUS

CN Valinamide, N-[3-(aminoiminomethyl)phenyl]glycyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 328550-99-8 CAPLUS


CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]-O-ethyl-3-oxoseryl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

10081009




●x HCl

RN 328551-18-4 CAPLUS
CN Valinamide, N-[3-(aminoiminomethyl)phenyl]alanyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 328551-47-9 CAPLUS
CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]-3-hydroxyhomoseryl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 328551-87-7 CAPLUS
CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]-2-(2-pyridinyl)glycyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)


10081009



● x HCl

RN 328551-91-3 CAPLUS


CN Glycinamide, N-[3-(aminoiminomethyl)phenyl]-2-cyclopropylglycyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 328552-38-1 CAPLUS

CN Valinamide, N-[3-(aminoiminomethyl)phenyl]-2-(1H-pyrazol-3-yl)glycyl-N-[2-(1H-indol-3-yl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)




x HCl

10081009

RN 328552-49-4 CAPLUS

CN Valinamide, N-[3-(aminoiminomethyl)phenyl]valyl-N-[2-(1H-indol-3-yl)ethyl]-
, hydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1994:218554 CAPLUS

DOCUMENT NUMBER: 120:218554

TITLE: Preparation of peptide mimics useful as platelet
aggregation inhibitors

INVENTOR(S): Bovy, Philippe Roger; Garland, Robert Bruce; Miyano,
Masateru; Rico, Joseph Gerace; Rogers, Thomas Edward;
Zablocki, Jeffery Alan

PATENT ASSIGNEE(S): Searle, G. D., and Co., USA; Monsanto Co.

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318058	A1	19930916	WO 1993-US1710	19930302
W:	AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US			
RW:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG			
AU 9337787	A1	19931005	AU 1993-37787	19930302
US 5453440	A	19950926	US 1993-138559	19931015
US 5550159	A	19960827	US 1995-444337	19950518
PRIORITY APPLN. INFO.:			US 1992-847260	19920306
			WO 1993-US1710	19930302
			US 1993-138559	19931015

OTHER SOURCE(S): MARPAT 120:218554
GI



- AB Title compds. [I; R1, R2, R3 = H, alkyl, (substituted) Ph, benzoheterocyclyl; A = (substituted) alkylene, alkenylene, alkynylene; W = H, methoxyalkyl, alkyl, cycloalkyl; Y = H, carboxyl, alkoxycarbonyl; Z, Z1, Z2 = halo, alkoxy, alkyl, CF3, H, OH; q = 0-3] were prepd. Thus, 4-aminobenzimidine dihydrochloride was coupled with succinic anhydride in pyridine contg. dimethylaminopyridine to give 4-[H2NC(:NH)]C6H4NHCOCH2CH2CO2H. This was coupled with aspartame using N-methylmorpholine/isobutyl chloroformate/dimethylaminopyridine in DMF to give title compd. II. II inhibited ADP-induced aggregation of canine platelet-rich plasma with IC50 = 0.09 .mu.M.
- IT **153982-05-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as blood platelet aggregation inhibitor)
- RN 153982-05-9 CAPLUS
- CN Butanoic acid, 3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-[[2-(1H-indol-3-yl)ethyl]amino]-4-oxo-, (S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



- IT **153982-12-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as intermediate for blood platelet aggregation inhibitor)
- RN 153982-12-8 CAPLUS

10081009

CN Butanoic acid, 3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-[[2-(1H-indol-3-yl)ethyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

